propylene glycol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4024 57-55-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propane-1,2-diol
  • 1,2-propanediol
  • 1,2-propylene glycol
  • propylene glycol
A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
  • Molecular weight: 76.10
  • Formula: C3H8O2
  • CLOGP: -1.06
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: 1.10
  • ROTB: 1

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye irritation 192.10 19.65 62 2993 21909 63464058
Eye pain 80.38 19.65 37 3018 33817 63452150
Foreign body sensation in eyes 79.49 19.65 19 3036 2215 63483752
Ocular hyperaemia 70.90 19.65 31 3024 25113 63460854
Pneumonia viral 63.64 19.65 21 3034 7901 63478066
Instillation site pain 61.17 19.65 13 3042 891 63485076
Breath sounds abnormal 60.66 19.65 22 3033 10951 63475016
Eye discharge 56.54 19.65 18 3037 6045 63479922
Cardiac murmur 51.19 19.65 21 3034 14531 63471436
Eye pruritus 49.33 19.65 22 3033 18649 63467318
Erythema of eyelid 49.18 19.65 13 3042 2273 63483694
Dry eye 48.51 19.65 28 3027 40733 63445234
Presyncope 46.73 19.65 24 3031 27761 63458206
Eosinophilia 45.17 19.65 22 3033 22734 63463233
Nasal congestion 38.56 19.65 29 3026 65631 63420336
Vision blurred 37.88 19.65 33 3022 91891 63394076
Chronic obstructive pulmonary disease 33.11 19.65 26 3029 62660 63423307
Scleral hyperaemia 30.22 19.65 6 3049 293 63485674
Anaemia vitamin B12 deficiency 28.20 19.65 6 3049 413 63485554
Keratitis 27.19 19.65 9 3046 3413 63482554
Eyelids pruritus 26.99 19.65 7 3048 1135 63484832
Lacrimation increased 26.76 19.65 15 3040 20616 63465351
Productive cough 26.64 19.65 23 3032 63185 63422782
Visual acuity reduced 25.97 19.65 15 3040 21811 63464156
Photophobia 23.35 19.65 13 3042 17622 63468345
Upper respiratory tract infection 23.33 19.65 24 3031 82023 63403944
Eye swelling 22.16 19.65 14 3041 23904 63462063
Intraocular pressure increased 22.15 19.65 9 3046 6069 63479898
Eyelid irritation 21.30 19.65 5 3050 538 63485429
Eyelid oedema 20.39 19.65 10 3045 10469 63475498
Blood sodium abnormal 19.92 19.65 5 3050 712 63485255

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 142.25 31.79 42 2129 8559 34946201
Appendicitis 119.81 31.79 42 2129 14765 34939995
Ventricular fibrillation 101.90 31.79 42 2129 22912 34931848
Stress 100.10 31.79 45 2126 30302 34924458
Blood phosphorus increased 98.93 31.79 31 2140 7690 34947070
Cardiogenic shock 95.90 31.79 42 2129 26576 34928184
Myasthenia gravis 93.68 31.79 29 2142 6911 34947849
Ocular procedural complication 83.64 31.79 12 2159 55 34954705
Blood uric acid increased 80.48 31.79 28 2143 9596 34945164
Ascites 76.33 31.79 43 2128 46528 34908232
Abdominal distension 69.76 31.79 44 2127 58448 34896312
Dry mouth 69.59 31.79 35 2136 30130 34924630
Blood cholesterol increased 59.92 31.79 28 2143 20515 34934245
Hyponatraemia 58.18 31.79 45 2126 82646 34872114
Multiple organ dysfunction syndrome 56.78 31.79 43 2128 76523 34878237
Constipation 47.46 31.79 50 2121 136932 34817828
Iron deficiency 42.45 31.79 15 2156 5366 34949394
Hyperphosphataemia 41.31 31.79 14 2157 4423 34950337
Incorrect route of product administration 39.49 31.79 19 2152 14826 34939934
Abdominal pain 38.60 31.79 49 2122 163569 34791191
Sepsis 37.91 31.79 49 2122 166512 34788248
General physical health deterioration 37.75 31.79 43 2128 128226 34826534
Keratitis 37.21 31.79 10 2161 1441 34953319
Drug therapy 34.69 31.79 9 2162 1132 34953628
Neuralgia 33.24 31.79 17 2154 15096 34939664
Hypophosphataemia 32.03 31.79 15 2156 11011 34943749

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 146.46 22.74 42 4437 8509 79731400
Eye irritation 120.94 22.74 45 4434 20636 79719273
Appendicitis 109.82 22.74 42 4437 20752 79719157
Blood phosphorus increased 96.96 22.74 32 4447 10315 79729594
Ventricular fibrillation 92.43 22.74 42 4437 31884 79708025
Myasthenia gravis 88.85 22.74 30 4449 10369 79729540
Ocular procedural complication 86.20 22.74 16 4463 465 79739444
Cardiogenic shock 84.46 22.74 43 4436 41871 79698038
Blood uric acid increased 77.82 22.74 29 4450 13331 79726578
Stress 65.89 22.74 46 4433 79566 79660343
Ascites 63.32 22.74 44 4435 75518 79664391
Ocular hyperaemia 62.87 22.74 31 4448 28175 79711734
Chronic obstructive pulmonary disease 60.71 22.74 45 4434 85374 79654535
Pneumonia viral 57.46 22.74 21 4458 9137 79730772
Keratitis 55.51 22.74 17 4462 4305 79735604
Multiple organ dysfunction syndrome 53.08 22.74 48 4431 120198 79619711
Breath sounds abnormal 49.32 22.74 22 4457 15962 79723947
Dry mouth 48.71 22.74 40 4439 87979 79651930
Foreign body sensation in eyes 47.92 22.74 13 4466 2144 79737765
Cardiac murmur 46.35 22.74 21 4458 15803 79724106
Abdominal distension 45.55 22.74 44 4435 119606 79620303
Eye pain 41.46 22.74 26 4453 37552 79702357
Erythema of eyelid 41.21 22.74 12 4467 2558 79737351
Instillation site pain 39.66 22.74 9 4470 714 79739195
Eye discharge 38.46 22.74 14 4465 6020 79733889
Hyperphosphataemia 37.70 22.74 14 4465 6362 79733547
Hyponatraemia 35.93 22.74 47 4432 177801 79562108
Drug therapy 35.12 22.74 9 4470 1192 79738717
Presyncope 34.58 22.74 24 4455 41030 79698879
Iron deficiency 33.95 22.74 15 4464 10639 79729270
Incorrect route of product administration 33.18 22.74 22 4457 34907 79705002
Blood cholesterol increased 32.24 22.74 31 4448 83689 79656220
Analgesic therapy 31.66 22.74 8 4471 1001 79738908
Sleep disorder therapy 31.55 22.74 8 4471 1016 79738893
Visual acuity reduced 31.53 22.74 20 4459 29449 79710460
Nasal congestion 30.72 22.74 29 4450 76523 79663386
Sepsis 30.00 22.74 54 4425 269374 79470535
Dry eye 29.73 22.74 21 4458 36910 79702999
Corneal disorder 29.37 22.74 9 4470 2282 79737627
Constipation 29.33 22.74 55 4424 282995 79456914
Corneal epithelium defect 29.13 22.74 7 4472 712 79739197
Eosinophilia 28.03 22.74 22 4457 45323 79694586
Hypophosphataemia 27.71 22.74 16 4463 19897 79720012
Ulcerative keratitis 25.16 22.74 9 4470 3680 79736229
Upper respiratory tract infection 24.75 22.74 28 4451 91140 79648769
Neuralgia 24.62 22.74 18 4461 33366 79706543
Anaemia vitamin B12 deficiency 23.51 22.74 6 4473 782 79739127
General physical health deterioration 23.11 22.74 49 4430 275189 79464720
Somnolence 22.97 22.74 45 4434 238936 79500973
Vision blurred 22.95 22.74 29 4450 105869 79634040

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:48356 protogenic solvent
CHEBI has role CHEBI:50904 alergeno
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76967 human xenobiotic metabolites
MeSH PA D010592 Pharmaceutic Aids
MeSH PA D014677 Pharmaceutical Vehicles
MeSH PA D012997 Solvents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009
Keratoconjunctivitis sicca off-label use 302896008 DOID:12895




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017526 VUID
N0000145910 NUI
D00078 KEGG_DRUG
4017526 VANDF
C0072225 UMLSCUI
CHEBI:16997 CHEBI
CHEMBL286398 ChEMBL_ID
D019946 MESH_DESCRIPTOR_UI
DB01839 DRUGBANK_ID
6DC9Q167V3 UNII
1030 PUBCHEM_CID
34693 RXNORM
NOCODE MMSL
002468 NDDF
13668001 SNOMEDCT_US
411259004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Systane Lubricant HUMAN OTC DRUG LABEL 2 0065-0429 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane Lubricant HUMAN OTC DRUG LABEL 2 0065-0429 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane HUMAN OTC DRUG LABEL 2 0065-0431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane HUMAN OTC DRUG LABEL 2 0065-0431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane HUMAN OTC DRUG LABEL 2 0065-0454 GEL 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane HUMAN OTC DRUG LABEL 2 0065-0454 GEL 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane COMPLETE HUMAN OTC DRUG LABEL 1 0065-0481 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane COMPLETE HUMAN OTC DRUG LABEL 1 0065-0481 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane Ultra HUMAN OTC DRUG LABEL 2 0065-1431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane Ultra HUMAN OTC DRUG LABEL 2 0065-1431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane Ultra HUMAN OTC DRUG LABEL 2 0065-1431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane Ultra HUMAN OTC DRUG LABEL 2 0065-1431 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
SystaneULTRA HUMAN OTC DRUG LABEL 2 0065-1432 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 12 sections
SystaneULTRA HUMAN OTC DRUG LABEL 2 0065-1432 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 12 sections
Systane Balance HUMAN OTC DRUG LABEL 1 0065-1433 EMULSION 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane Balance HUMAN OTC DRUG LABEL 1 0065-1433 EMULSION 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane Balance HUMAN OTC DRUG LABEL 1 0065-1433 EMULSION 0.06 mg OPHTHALMIC OTC monograph final 12 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE HUMAN OTC DRUG LABEL 2 0065-1437 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE HUMAN OTC DRUG LABEL 2 0065-1437 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane Ultra Preservative Free HUMAN OTC DRUG LABEL 2 0065-1507 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 12 sections
Systane Ultra Preservative Free HUMAN OTC DRUG LABEL 2 0065-1507 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 12 sections
Systane COMPLETE PF HUMAN OTC DRUG LABEL 1 0065-1509 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane COMPLETE PF HUMAN OTC DRUG LABEL 1 0065-1509 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE HUMAN OTC DRUG LABEL 2 0065-1510 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE HUMAN OTC DRUG LABEL 2 0065-1510 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
SYSTANE HYDRATION PF PRESERVATIVE FREE HUMAN OTC DRUG LABEL 2 0065-1510 SOLUTION/ DROPS 3 mg OPHTHALMIC OTC monograph final 13 sections
Systane COMPLETE PF HUMAN OTC DRUG LABEL 1 0065-1530 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane COMPLETE PF HUMAN OTC DRUG LABEL 1 0065-1530 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
Systane COMPLETE PF HUMAN OTC DRUG LABEL 1 0065-1530 SOLUTION/ DROPS 0.06 mg OPHTHALMIC OTC monograph final 12 sections
GenTeal Tears Gel Drops HUMAN OTC DRUG LABEL 2 0065-8067 GEL 3 mg OPHTHALMIC OTC monograph final 13 sections